A call for replicating vector prime-protein boost strategies in HIV vaccine design.

Abstract:

:A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV envelope glycoprotein. This is difficult due to the envelope's conformational complexity and sequence diversity. Antibodies that do not completely prevent infection nevertheless could reduce the viral infectious burden, allowing strong cellular immunity to control viremia, delay disease progression and prevent viral transmission, while also providing help for T- and B-cell responses. Rapidly responsive, potent, persistent immunity might best be achieved using prime-boost strategies incorporating a replicating vector and an optimally designed envelope subunit.

journal_name

Expert Rev Vaccines

authors

Malkevitch NV,Robert-Guroff M

doi

10.1586/14760584.3.4.s105

keywords:

subject

Has Abstract

pub_date

2004-08-01 00:00:00

pages

S105-17

issue

4 Suppl

eissn

1476-0584

issn

1744-8395

pii

ERV0304S10

journal_volume

3

pub_type

杂志文章,评审
  • PSA-based vaccines for the treatment of prostate cancer.

    abstract::Prostate cancer is the second leading cause of cancer-related death among men in the USA. Vaccine strategies represent a novel therapeutic approach. One potential target for a prostate cancer vaccine is prostate-specific antigen, owing to its restricted expression in prostate cancer and normal prostatic epithelial cel...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.2.199

    authors: Madan RA,Gulley JL,Arlen PM

    更新日期:2006-04-01 00:00:00

  • Varicella prevention in Costa Rica: impact of a one-dose schedule universal vaccination.

    abstract:INTRODUCTION:To describe the impact following a 1-dose Varicella vaccination schedule introduced in Costa Rica in September 2007. Areas covered: This is a retrospective review using epidemiologic surveillance national databases of varicella cases and hospitalizations, period 2000-2015. We analyzed age-related varicella...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1247700

    authors: Avila-Aguero ML,Ulloa-Gutierrez R,Camacho-Badilla K,Soriano-Fallas A,Arroba-Tijerino R,Morice-Trejos A

    更新日期:2017-03-01 00:00:00

  • The RTS,S vaccine candidate for malaria.

    abstract::Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine for...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.57

    authors: Regules JA,Cummings JF,Ockenhouse CF

    更新日期:2011-05-01 00:00:00

  • Development of Group A streptococcal vaccines: an unmet global health need.

    abstract::Group A Streptococcus (GAS) infections are a significant global cause of morbidity and mortality. GAS diseases disproportionally affect those living in conditions characterized by poverty and social injustice, in both developing countries and in marginalized populations of industrialized nations. In Australia and New ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1116946

    authors: Sheel M,Moreland NJ,Fraser JD,Carapetis J

    更新日期:2016-01-01 00:00:00

  • Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.

    abstract::Dr Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (BTG; Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/erv.10.2

    authors: Ben-Yedidia T

    更新日期:2010-03-01 00:00:00

  • DNA-launched live-attenuated vaccines for biodefense applications.

    abstract::A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1175943

    authors: Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

    更新日期:2016-09-01 00:00:00

  • Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies.

    abstract::This review deals with specific immunotherapy performed with pollen vaccines. Pollen allergens, the immunological mechanism of allergic inflammation and the mechanisms behind successful specific immunotherapy treatment of seasonal pollen allergy shall be discussed. The different approaches to develop improved regimes ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.1.85

    authors: Movérare R

    更新日期:2003-02-01 00:00:00

  • Clinical peptide vaccination trials for leukemia patients.

    abstract::The favorable graft-versus-leukemia (GVL) effect that occurs after stem cell transplantation suggests that T cells can eradicate leukemia blasts. T cells specifically recognize peptides and exert an antileukemia effect. Several leukemia-associated antigens (LAAs) have been found to be overexpressed in malignant cells ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.56

    authors: Casalegno-Garduño R,Schmitt A,Schmitt M

    更新日期:2011-06-01 00:00:00

  • ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines.

    abstract::This review describes several enzyme-linked immunosorbent assay (ELISA) techniques proposed to replace the neutralization test for detecting neutralization-relevant antibodies to polioviruses in recipients of inactivated poliovirus vaccine and oral poliovirus vaccine, and for seroepidemiologic studies. Comparisons of ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.2.167

    authors: Ivanov AP,Dragunsky EM

    更新日期:2005-04-01 00:00:00

  • Vaccines in leishmaniasis: advances in the last five years.

    abstract::The leishmaniases are a group of diseases caused by protozoa of the genus Leishmania which affects millions of people worldwide. The leishmaniases are transmitted to the vertebrate hosts by phlebotomine sand flies. In this review, we focus on clinical aspects of the leishmaniases and on the immune response against the...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.5.705

    authors: Brodskyn C,de Oliveira CI,Barral A,Barral-Netto M

    更新日期:2003-10-01 00:00:00

  • Antigen delivery systems.

    abstract::Many vaccine candidates are highly purified, sometimes monomeric antigens and as a result, not very immunogenic. Antigen delivery systems optimize the presentation of antigens. They also play a major role in solving the problem of there being an increasing number of vaccines but limited opportunities in which to inclu...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.453

    authors: Kersten G,Hirschberg H

    更新日期:2004-08-01 00:00:00

  • Innate immune control of nucleic acid-based vaccine immunogenicity.

    abstract::Optimal vaccine efficacy requires not only a protective antigen, but also a strong immune activator as an adjuvant. Most viral vaccines, such as influenza vaccines and nonviral genetic vaccines (e.g., DNA vaccines), contain nucleic acids, which appear to act as essential 'built-in' adjuvants. Specific receptors, inclu...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.57

    authors: Koyama S,Coban C,Aoshi T,Horii T,Akira S,Ishii KJ

    更新日期:2009-08-01 00:00:00

  • Prospects for vaccine development against Buruli disease.

    abstract::Buruli disease, caused by Mycobacterium ulcerans, is an emerging infectious disease in tropical areas, particularly West Africa, which can cause deep necrotizing skin lesions, called Buruli ulcer. Buruli disease affects all age groups but about 50% of the cases are diagnosed in children. There is no evidence that Buru...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.4.561

    authors: Huygen K

    更新日期:2003-08-01 00:00:00

  • Fluzone® High-Dose Influenza Vaccine.

    abstract:INTRODUCTION:Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1254044

    authors: Robertson CA,DiazGranados CA,Decker MD,Chit A,Mercer M,Greenberg DP

    更新日期:2016-12-01 00:00:00

  • Current challenges in the development of vaccines for pneumonic plague.

    abstract::Inhalation of Yersinia pestis bacilli causes pneumonic plague, a rapidly progressing and exceptionally virulent disease. Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.2.209

    authors: Smiley ST

    更新日期:2008-03-01 00:00:00

  • Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

    abstract::Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vac...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.4

    authors: Rimmelzwaan GF,Sutter G

    更新日期:2009-04-01 00:00:00

  • Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric.

    abstract:INTRODUCTION:Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increas...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1580578

    authors: Bravo C,Mege L,Vigne C,Thollot Y

    更新日期:2019-03-01 00:00:00

  • Current challenges for cancer vaccine adjuvant development.

    abstract:INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1434000

    authors: Bowen WS,Svrivastava AK,Batra L,Barsoumian H,Shirwan H

    更新日期:2018-03-01 00:00:00

  • In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

    abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1599286

    authors: Berkhout A,Clark JE,Wen SC

    更新日期:2019-05-01 00:00:00

  • FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.

    abstract::The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.6.833

    authors: Palatnik-de-Sousa CB,Barbosa Ade F,Oliveira SM,Nico D,Bernardo RR,Santos WR,Rodrigues MM,Soares I,Borja-Cabrera GP

    更新日期:2008-08-01 00:00:00

  • Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

    abstract::The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approv...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1099437

    authors: Wei XX,Fong L,Small EJ

    更新日期:2015-01-01 00:00:00

  • Alternative administration routes and delivery technologies for polio vaccines.

    abstract::Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccin...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1158650

    authors: Kraan H,van der Stel W,Kersten G,Amorij JP

    更新日期:2016-08-01 00:00:00

  • New challenges in therapeutic vaccines against HIV infection.

    abstract:INTRODUCTION:There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1322513

    authors: Leal L,Lucero C,Gatell JM,Gallart T,Plana M,García F

    更新日期:2017-06-01 00:00:00

  • Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.

    abstract::Introduction Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world. Areas covered This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal, and tuberculosis vaccines...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2020.1825951

    authors: Sultana J,Mazzaglia G,Luxi N,Cancellieri A,Capuano A,Ferrajolo C,de Waure C,Ferlazzo G,Trifirò G

    更新日期:2020-10-01 00:00:00

  • Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.

    abstract::More focused research on a mucosal HIV-1 vaccine is needed urgently. An increasing amount of collected data, using heterologous multimodality prime-booster strategies, suggest that an efficient and protective HIV-1 vaccine must generate broad, long-lasting HIV-specific CD8(+) cytotoxic T-lymphocyte and neutralizing an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.2.203

    authors: Hinkula J

    更新日期:2007-04-01 00:00:00

  • BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control.

    abstract::The bacillus Calmette-Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses did not provide a summary estimate of the efficacy due to the heterogeneity of the results. We conducted a meta-analysis of pu...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析

    doi:10.1586/erv.09.161

    authors: Merle CS,Cunha SS,Rodrigues LC

    更新日期:2010-02-01 00:00:00

  • Plant production systems for vaccines.

    abstract::Plants offer an attractive alternative for the production and delivery of subunit vaccines. Various antigens have been expressed at sufficiently high levels in plants to render vaccine development practical. An increasing body of evidence demonstrates that these plant-produced antigens can induce immunogenic responses...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.6.763

    authors: Streatfield SJ,Howard JA

    更新日期:2003-12-01 00:00:00

  • Immunization: a global challenge for the 21st Century.

    abstract::The 9th Canadian Immunization Conference was held on 5-8 December 2010 in Quebec City, Canada. Over 1000 academic, public health and vaccine industry scientists, nurses, pharmacists, physicians and policy makers attended the conference, which was organized by the Public Health Agency of Canada-Centre for Immunization ...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.11.34

    authors: Langley JM,Naus M

    更新日期:2011-04-01 00:00:00

  • TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.

    abstract::Vaccination has been a successful tool in the protection against many infectious diseases, and recent advances in biotechnology have created new techniques and strategies to produce safe and efficacious vaccines for human use. However, developing a protective vaccine against malaria has been a challenge. In this artic...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.60

    authors: Coban C,Horii T,Akira S,Ishii KJ

    更新日期:2010-07-01 00:00:00

  • Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.

    abstract::Streptococcus pneumoniae, the most common cause of community-acquired pneumonia, remains a major cause of morbidity and mortality worldwide. The presence of chronic respiratory illness is a major risk factor for pneumonia, and smoking (the most common cause of chronic obstructive pulmonary disease) is also an importan...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.176

    authors: Vila-Corcoles A,Ochoa-Gondar O

    更新日期:2012-02-01 00:00:00